All posts by Turacoz Group

Chitkara University and Turacoz Healthcare Solutions: Memorandum of Understanding

India – Turacoz Skill Development Program (TSDP) is an initiative of Turacoz Healthcare Solutions, a knowledge partner for medical evidence creation and writing documents for pharmaceuticals, biotechnology companies, publishing houses, societies and associations and academics. Turacoz team consists of well-experienced medical writers, editors, reviewers, business development experts, statisticians, project managers, social media and digital marketing experts, analytics, management information system experts, and healthcare professionals with expertise across all major therapeutic areas and various types of job requirements.

[dt_button size=”small” style=”default” animation=”none” color_mode=”default” icon=”” icon_align=”left” color=”” link=”https://www.media.onlineprnews.com/news/1106556-1525687528-chitkara-university-and-turacoz-healthcare-solutions-memorandum-of-understanding.html” target_blank=”true”]Read More[/dt_button]

Turacoz Healthcare Solutions Picks Acceliant to Strengthen Clinical Trial Offerings

Acceliant, the global leader in e-clinical data management solutions, has partnered with Turacoz, a leading medical communications company that provides customized, cost-effective solutions to the healthcare and pharmaceutical industries.

Turacoz will leverage its association with Acceliant to strengthen its technological capabilities in PMS, registry, observational and real-world evidence studies globally.

[dt_button size=”small” style=”default” animation=”none” color_mode=”default” icon=”” icon_align=”left” color=”” link=”https://www.prnewswire.com/news-releases/turacoz-healthcare-solutions-picks-acceliant-to-strengthen-clinical-trial-offerings-648454633.html” target_blank=”true”]Read More[/dt_button]

Life Sciences Sector Skill Development Council (LSSSDC) and Turacoz Healthcare Solutions Pvt. Ltd.

Turacoz Healthcare Solutions, a medical communications company provides customized and cost-effective services for various types of medical writing documents. A team of young, dynamic, and energetic professionals contribute to the core service spectrum which includes publication writing; clinical research and regulatory writing; print and digital marketing solutions; and medical content development for physicians, key opinion leaders (KOLs), education institutes, pharmaceutical organizations, or any other healthcare professionals.

[dt_button size=”small” style=”default” animation=”none” color_mode=”default” icon=”” icon_align=”left” color=”” link=”http://www.pressbox.co.uk/Arts/Life_Sciences_Sector_Skill_Development_Council_LSSSDC_and_Turacoz_Healthcare_Solutions_Pvt._Ltd.__1974075.html” target_blank=”true”]Read More[/dt_button]

Women`s Health Confluence Prevention and Cure of Cancers & Thyroid Disorders

Women are pivotal contributors to society in their roles as mothers, individuals, family members, and as citizens. When a woman’‘s health is poor, her contribution to society is decreased. A woman’‘s health is critical to the well-being of her family and to the economy of her community and her country. Investing in the health of women is not only the right thing to do; it also builds stable, peaceful and productive societies.

[dt_button size=”small” style=”default” animation=”none” color_mode=”default” icon=”” icon_align=”left” color=”” link=”http://www.assocham.org/eventdetail.php?id=1404″ target_blank=”true”]Read More[/dt_button]

‘World No Tobacco Day’ (31st May 2018): Tobacco and Heart Disease.

World No Tobacco Day (WNTD) is celebrated every year on 31st May, since its beginning in 1988. The main aim to mark this day is to encourage a 24-hour period of abstinence from all forms of tobacco consumption around the world. It also aims to spread awareness about the widespread prevalence of tobacco use and the health risks associated with tobacco consumption. The resolution to celebrate 31 May as WNTD was passed by the World Health Assembly (WHA) in 1998 (WHA40.38). The World Health Organization (WHO) has continuously supported WNTD, every year for this campaign and decides on a theme for the day to create a more unified global message. The global theme for WNTD 2018 is – “Tobacco and Heart disease”. The theme focuses on the association between tobacco consumption and cardiovascular health and aims to inculcate the sense of refraining from tobacco use among general people.

Tobacco contains nicotine, a drug classified as potent parasympathomimetic stimulant. Nicotine is a poisonous alkaloid of the plant genus Nicotiana (family Solanaceae). The WHO declared tobacco as the world’s single greatest preventable cause of death in 2008.

Tobacco use is an important risk factor for the development of various diseases such as cancers (lung, blood, kidney, bladder, brain etc.), respiratory diseases, cardiovascular diseases (CVDs), coronary heart disease (CHD), stroke, peripheral vascular disease, pregnancy complications etc.

Key Facts from 2017 World Tobacco Reports

  • Worldwide, each year tobacco causes nearly 6 million deaths, and current trends show that tobacco use lead to more than 8 million deaths annually by 2030.
  • Almost every child regularly breathe air polluted by tobacco smoke in public places.
  • As per the WHO’s, Global Health Observatory (GHO) data 2016, 40% of children are exposed to second-hand tobacco smoke, accounting for over 600,000 deaths per year. Close to a third of those deaths were reported in children under the age of five and two-thirds were in Sub-Saharan Africa (SSA) and South Asia.
  • In 2011, tobacco caused one-tenth of CVDs worldwide. About 12% of all heart disease deaths are due to the use of tobacco and second-hand smoke.
  • After high blood pressure, tobacco use is the second leading cause of CVD.

Aim of the World No Tobacco Day 2018

  • Highlighting the connection between the use of tobacco products and CVDs.
  • Increasing awareness within the masses to refrain from tobacco use and resist exposure to second-hand smoke to improve their cardiovascular health.
  • Promoting heart health by feasible government actions and public measures that can help to reduce the risks to heart health posed by tobacco.
  • Encouraging countries to include tobacco control in their national agenda.

Turacoz healthcare solutions, aims to increase awareness about the negative health impact of tobacco consumption and motivate them to refrain from the use of tobacco products. We must all join hands and raise our voice against both active and passive smoking so that a brighter and healthier future can be ensured for our younger generation and our Nation. Turacoz is a medical communications company, which offers services to healthcare professionals in clinical research, regulatory writing, publication writing, medico-marketing writing, and support for conducting medical advisory board meetings.

Graphical Abstract

What is graphical abstract?

Graphical abstract is a concise and visual/pictorial summary of the main findings of any publication manuscript. It helps readers to understand the findings of a manuscript in a better way and in a simplified manner. They are not replacements of traditional textual abstracts instead are an addition to them.

Why Graphical Abstract?

Graphical abstract should not be considered as a burden or waste of time by the authors. Therefore, it is necessary for them to understand the rationale behind the use of graphical abstract. Graphical abstract is a well-suited platform to share or disseminate the research via social media in today’s time and help attract the readers to encourage them to further read the article. Graphical abstract can help reader to quickly get the take-home message.

Hullan et al. analyzed 54 graphical abstracts and outlined the common patterns of graphical abstract designs observed in published literature. They include:

  1. Process illustrations: The most common layout presenting the processes “using (hand‑crafted) illustrations on a linear or forking layout”.
  2. Result representation: Data visualizations in the form of line charts to depict research results was used by numerous graphical abstracts.
  3. Parallel layouts: These graphical abstracts include “parallel pictures laid out horizontally on the graphical abstract plane”.

Recently, the use of graphical abstract is gaining momentum. A recent study by Pferschy‑Wenzig et al. compared the visibility of manuscripts published with graphical abstracts with that of publications without the one in the journal ‘Molecules’. The study found that the manuscripts published without graphical abstract had significantly higher abstract views, PDF downloads, and total citations. However, this study included the comparison of research from a limited timeframe and also focused on one journal. Future research on other journals comparing research from longer time periods is warranted.

Some tips for designing a graphical abstract

  1. Always refer to the journals guidelines to check specifications for graphical abstracts. For example; Elsevier has the specifications on image size, font, file type
  2. Refer to the examples of graphical abstract from the publisher and see the one to which the new study matches and design it accordingly. Elsevier has enlisted 16 good examples of graphical abstracts for articles published in their journals
  3. Keep it simple and to one image only
  4. Focus on the design and composition
  5. Stay away from using saturated distracting colors for the abstract
  6. Graphical abstract should present the results of the study rather than the method used to obtain the results or the referenced literature, unless necessary
  7. Must be self-explanatory
  8. Must include keywords in the image
  9. Microsoft paint, Microsoft PowerPoint, adobe illustrator, ChenDraw, Coreldraw can be used to design graphical abstract. Several software available online can also be used, such as Mind the Graph, Inkscape etc.
  10. You can also refer to agencies offering services for graphical abstract designing

Turacoz Healthcare Solutions (THS) is a medical writing agency with specialized medical writing and editing services of Publication writing, Regulatory writing, and Medico-marketing document for the pharma industry. This blog aims to spread awareness about the increasing use of graphical abstracts in publications and its role in disseminating the published research information to a wide audience via online media.

Relationship Building at Workplace

Our current lifestyle revolves around our workplace duties and responsibilities. Every day we spend the major part of our time at our workplace. In order to have a satisfying job, we must enjoy the work. Maximum output and increased productivity can only be achieved if we have a healthy working environment. Work becomes burden if we don’t have people around to talk to or discuss and brainstorm ideas. Also, it is okay to trust our colleagues, provided we don’t cross our limits and disclose confidential matters.

Let us look at the various impacts of relationship building at workplace:

  • A knowledgeable individual is one who on one hand improvises on the negative qualities of his/her colleague and on the other glorifies their strengths. This trait helps in resolving conflicts. Conflicts at work place lead to no solutions whereas on the other hand nice gesture sets things straight.
  • As a mature professional, one needs to keep a check on his/her emotions. One must learn to ignore negative people or sit with him/her and try to mutually sort out their differences.
  • Managers must have a healthy relationship with their subordinates. Listening to them closely, helps the subordinates to strive hard and perform better. Doing this, a good manager can ensure their team’s performance is the best under all situations.
  • Knowledge sharing is important factor governing career excellence. Sharing with the team is a two-way learning process.
  • An individual need to be a team player and pay attention to other team member ideas as well.
  • Unnecessary conflicts and misunderstandings at workplace lead to stress. An individual would never be able to deliver his/her level best if she/he is under stress.

Importance of Relationship Building

  • Healthy relationship is the key to positive ambience at workplace.
  • Healthy relationship goes a long way in extracting the best out of individuals.
  • Healthy relationship leads to mental peace. One tends to enjoy his/her work if he/she has a trustable environment.
  • Healthy relationship leads to people from varied backgrounds and expertise come together on a common platform, exchange ideas and reach to best possible solutions and strategies.
  • Healthy relationship among employees also goes a long way in inculcating a sense of pride and loyalty for the organization. People tend to enjoy their work and office.
  • Healthy relationship among employees plays a crucial role at the time of crisis. Emergency situations are unpredictable and can arise anytime. It is necessary that people help each other for increased productivity and better output.

Relationship Building Approaches at Workplace:

  • Be honest in your relationships. Never lie to people you are close to.
  • Respect others. Superiors ought to respect their subordinates if they expect the same in return.
  • Never misguide If you feel your team member is going on the wrong track, guide him/her immediately. Give others the right suggestion.
  • It always pays to be straight forward in relationships. Never speak ill about someone behind their back.
  • Be transparent in relationships. A senior need to be transparent with his/her subordinates and vice a versa. Favoritisms should be avoided.
  • One needs to communicate effectively for successful relationships. The other person must understand what you intend to communicate.
  • Learn to say a polite yet firm ‘NO’ to people.
  • Leave your ego behind the moment you step inside the office. Be kind to each and every-one. It pays in the long run.
  • Learn to forgive
  • Motivate each other and avoid being jealous. Help each other at the times of crisis.
  • Develop a habit of working in teams. Responsibilities ought to be distributed equally among employees as per their expertise and work experience.
  • Do not open any of your team member’s personal files, couriers or letters just because he/she is your friend. Such an approach is unprofessional and unacceptable.

Turacoz Healthcare Solutions (THS) strongly believes in a transparent and healthy workplace environment. We understand the benefits of relationship building in today’s world and encourage everyone to be a team player. If you have the zeal for writing and enjoy working with a dynamic team visit us at https://turacoz.com/careers/.

 

World Malaria Day (25th April 2018)

“Ready to Beat Malaria”

World Malaria Day has become a global phenomenon and is celebrated on 25th April every year since its inception in 2007. This year’s global theme for World Malaria Day is ─ “Ready to Beat Malaria”. This theme encloses the universal goal of developing a malaria-free world. Further, it emphasizes the progress achieved in the past to tackle one of humanity’s oldest diseases; and at the same time grabs our attention towards the escalating trends reported in the 2017 World Malaria Report. After a remarkable period of success in controlling the spread of malarial cases, the progress appears to have slowed down. Hence, this year, World Health Organization (WHO) demands a greater expansion and investment of recognized tools that can prevent, diagnose, and treat malaria.

Malaria is an infectious disease caused by Plasmodium parasites that are transmitted to people through bite of infected female Anopheles mosquitoes (malaria vector). Initial symptoms include mild fever, headache, and chills, which might become lethal if left untreated for more than 24 hours. Severe malaria often leads to development of cerebral malaria or severe anaemia or involvement of multiple organs.

Statistical Facts according to the 2017 World Malaria Report:

  • In 2016, 216 million cases of malaria were estimated in 91 countries, corresponding to a surge of 5 million cases over those reported in 2015.
  • A total of 445,000 fatality cases were reported in 2016 compared to 446,000 in 2015.
  • In 2016, African regions shared a high global malaria burden, with 90% of malaria cases and 91% of mortality cases.
  • In 2016, India reported 6% of the world’s new malaria cases.

Prevention:

Transmission of malaria can be prevented and reduced with effective vector control. Vector control can be achieved in the following ways:

  • Insecticide-treated mosquito nets: WHO recommends the use of long-lasting insecticidal nets (LLINs) for people residing in areas at high risk of malaria. Pyrethroids are the only class of insecticides presently recommended for use in LLINs.
  • Indoor residual spraying with insecticides: This is a powerful method for rapid reduction of malaria transmission. The effect of indoor spraying persists for 3-6 months, depending on formulation of the insecticide used.
  • Antimalarial drugs: The travelers can use chemoprophylaxis as an effective method for prevention of malaria, as it suppresses the blood stage of malarial infections. WHO recommends the use of sulfadoxine-pyrimethamine for pregnant women at risk, and monthly courses of amodiaquine in addition to sulfadoxine-pyrimethamine for children at risk below 5 years during high transmission season.
  • Vaccines: Partial protection in children can be achieved by administration of an injectable vaccine “Mosquirix”. The vaccine is a complementary malaria tool rather than a replacement for treatment strategies.

Diagnosis and Treatment:

The diagnosis and treatment of malaria at an early stage limits transmission of the disease, reduces the risk of complications, and prevents death. Parasite-based diagnostic testing (either microscopy or rapid diagnostic test) is suggested by WHO prior to administering the treatment. Post-parasitological confirmation, artemisinin-based combination therapy (ACT) is used for treatment of Plasmodium falciparum malaria.

Turacoz Healthcare Solutions aims to spread awareness about malaria and strategies for its prevention, to aid ‘World Health Assembly’ achieve the global target of reducing 90% of incidence and mortality rates by 2030. Turacoz is a medical communications agency, which offers services to healthcare professionals in clinical research and regulatory writing, publication writing, medico-marketing writing, and support for conducting medical advisory board meetings.

Orphan Drugs: Global Market Scenario and Regulations

Global Market Scenario for Orphan Drugs

Orphan drugs are the drugs which are used for treatment of orphan/ rare diseases. After being neglected for a long time, the global market for orphan drugs is now witnessing a boom. The market is showing a constant growth and is expected to reach US$225 billion by 2024 due to recognition of their importance in healthcare. Other than this, the growth in orphan drugs is further attributed to recent advances in research modalities, increasing awareness and incidence of rare diseases, and improved incentives by regulatory authorities for development of orphan drugs. Favorable regulatory policies for orphan drug market in the United States have led to a fast growth of this market across the world. Pharmaceutical companies such as Actelion Pharmaceuticals Ltd., AbbVie, Inc., Alexion, Inc., Bayer AG and, AstraZeneca Plc are the key players in the orphan drug market.

Evolution of Orphan Drug Market Over the Years

As already mentioned, favorable regulations for the orphan drugs plays an important role in their increasing development and market growth. This is evident from the increasing numbers of orphan drugs in market from just 38 orphan drugs in 1983 to over 500 orphan drugs hitherto. Furthermore, over 230 orphan drugs had been approved by FDA in past decade and numbers are still increasing.

Development of Regulations and Guidelines for Orphan Drugs

Growth in orphan drug development led to emergence of US Orphan Drug Act 1983. With its’ successful outcomes, the act was then adopted by other nations in different customized forms. Below is the summary of the current regulations and guidelines for orphan drugs in different countries:

United States Orphan Drug Act

The act came into existence in 1983 and underwent further amendments in 1984, 1985, 1988, 1990 and, 1992. This act prioritized the treatment of rare diseases by facilitating research and development in field with provision of large amount of incentives for the same. Further, the act reduced the cost of developing new orphan drugs by wavering the fees at different stages of drug development such as new drug application fee, annual establishment and product fees after drug approval. Moreover, the act has a provision of tax credits on clinical research for orphan drugs along with the rights of exclusive marketing of product by pharmaceutical company for 7 years of development.

Japanese Orphan Drug Regulation

This act was formulated in 1993. As per these guidelines any drug would be categorized as orphan drug if it fulfills below mentioned criteria:

  • The disease targeted by orphan drug should be either incurable without any existing treatment or else the efficacy and safety profile of the new drug should surpass the ones already existing in market.
  • The prevalence of the rare condition must be less than 50,000; or the incidence must be 4/10,000 individuals.

The evaluation of new orphan drugs as per guidelines is done on priority basis resulting in fast track approvals and marketing authorizations. Further, pharmaceutical company would get added on incentives due to extended validity period of about 10 years. Moreover, reimbursement of 50% of drug development cost and waivers of taxes up to 6% on research and development of orphan drugs as per guidelines further ads onto the profits generation by pharmaceutical companies.

European Orphan Drug Act

This act came into existence in 1999. As per European Union (EU), the companies sponsoring orphan drug can participate in consultations and provide scientific advice related to development of orphan drugs. The fee for protocol assistance and follow-up is completely reduced by the act. Further the act waivered off all the fees for pre-authorization inspections. Moreover, there is provision for 50% reduction in fees on new marketing approval applications by large sized enterprises. The act also eliminated complete charges for not only marketing authorization, but post-approval charges are also wavered during the first year. However, this is applicable only to small and medium companies. Further profits to pharmaceutical companies can come from the provision of 10 years of exclusive marketing as per the act.

Turacoz Healthcare Solutions take an initiative to draw attention of healthcare providers and pharmaceutical companies towards the changing trend in global market scenario for orphan drugs. Further, this blog provides updated information about rules and regulations related to these drugs different countries. Turacoz provides high quality end to end scientific/medical writing support to the industry and academia. We expertise in several clinical trial related documents like Investigator Brochures (IBs), Protocols, Clinical Study Reports (CSRs), Clinical Evaluation Report (CER) and Common Technical Documents (CTDs) Prescribing Information (PI).

Medical Devices in Healthcare: Their Classification System and The Marketing Approval Process

Introduction

Medical device is an essential part of healthcare system. It is utilised for diagnosis, prevention and treatment of the disease as well as for patient care. It covers a broad range of products, starting from simple bandage to drug delivery pumps. Over the past two decades, the demand of safe and effective medical devices has increased tremendously. This has been achieved by constantly updating and improving the regulatory framework and implementing them in the process. Moreover, the regulatory authorities across the world are working towards smoothening of the process of registration of the medical devices.

Medical devices have different classification systems and marketing approval processes for different regions. The classification systems and marketing approval processes for United States of America (USA), Europe (EU) and Canada have been discussed below.

United States of America

The medical devices, in USA, are regulated by US Food and Drug Administration (USFDA), while the law, 21 CFR (code of federal regulation), describes the regulations of medical devices. FDA’s Centre for Devices and Radiological Health (CDRH) regularly monitors trends that point towards future product development and is responsible for pre- and post-market supervision of devices in US.

Classification of medical devices

US classifies medical devices into three categories:

  1. Class I General Controls
  • With Exemptions
  • Without Exemptions
  1. Class II General Controls and Special Controls
  • With Exemptions
  • Without Exemptions
  1. Class III General Controls and Premarket Approval

The USFDA has established classifications for approximately 1,700 different generic types of devices and grouped them into 16 medical specialties referred to as panels. A panel is assigned to determine the class of medical device and decides for the exception applicable to the device.

Marketing Approval Process

Firstly, the medical devices are classified according to the FDA searching database meeting the requirements of Quality system regulation (QSR) for which Quality management system (QMS) is implemented according to the 21 CFR part 820. Clinical trial data are submitted for some of the devices of class II and all the devices of class III followed by submission of Investigational Device Exemption (IDE) report followed by submission of 510(K) premarket notification or premarket approval application. Some premarket submissions such as PMA (Premarket Approval), De Novo (Evaluation of Automatic Class III Designation) and HDE (Humanitarian Device Exemption) are also required for submission, if applicable. Most of the devices under class II are required to submit 510(K) clearance form whereas, the devices under class III are required to submit PMA approval letter issued by FDA. Once all the clearance is submitted, FDA quality system inspects the manufacturing facilities for its compliance with QSRs. After that, the medical device listing and registration of competent company is done by using FURLS system on the FDA website in accordance with 21 CFR Part 807. The steps for issuing market approval for medical devices in the US are depicted in Figure 1.

 

Figure 1: Steps for medical devices market approval in the US

 

Europe

There is no single body in EU, as in India and USA, to regulate medical devices. However, a decentralized procedure of marketing authorization is followed in EU for regulating medical devices. A third party, i.e. notified bodies, is responsible for issuing Quality Assurance certificates as well as for assuring post-approval compliance to QMS.

European commission has established three directives which are regulated by Medical Devices Directives (MDD) and are allocated to regulate the safety and marketing of medical devices. The three directives are:

  • Medical Device Directive (MDD 93/42/EEC)
  • Active Implantable Medical Device Directive (AIMDD 90/42/EE)
  • In Vitro Diagnostic Medical Device Directive (IVDMDD 98/79/EC)

Classification of medical devices

Europe follows a risk-based classification system which are broadly classified into 3 classes:

  • Class I – Low risk
  • Class IIa – Medium risk
  • Class IIb – Medium/high risk
  • Class III -High risk

Marketing Approval process

The market approval of medical devices in Europe is very different from the regulations in US. First the EU derivative which applies to the medical devices is identified followed by the determination of the class of the medical device according to the Annex IX. For class II and III QMS is implemented for the device in accordance with Annex II or V of the MDD. An authorized representative of Europe is then appointed who can take care of all the regulatory issues. A notified body audits QMS and all the technical documents after which the device registration is done followed by the registration of the competent authority with EU member state. Declaration of Conformity is then prepared which ensures the compliance of medical device with applicable Directive. Finally CE mark certificate for the device is affixed and placed it in market. Additionally, a Conformité Européene or European Conformity (CE) mark certificate is required to commercialize medical devices. The steps required for market approval of medical device in Europe are shown in Figure 2:

 

Figure 2: Steps for medical devices market approval in Europe

 

Canada

The medical devices in Canada are regulated by Health Canada. Therapeutic Product Division (TPD) of health Canada classifies medical devices on the basis of Risk-Based Classification System (RBCS). Health Canada follows a four-class scheme to classify medical devices according to the risk to the human body. Among the four classes, medical devices that possess lowest risk on human body fall under class I while the medical devices with high risk fall under class IV.

Marketing approval in Canada

For issuing market approval of medical device in Canada, first the class of the medical device is determined i.e. from class I to IV in accordance with schedule 1, part 1 of the Canadian Medical Devices Regulations (CMDR) SOR/98-282 as published by Health Canada. Except for class 1 medical devices, implement an ISO 13485:2003 QMS for all the devices followed by audit. Health Canada generally issues two types of licences for market approval of medical devices. These are the Health Canada Medical Device Establishment License (MDEL) and the Health Canada Medical Device License (MDL). MDEL is required for the devices that come under class I while the devices of class II and IV needs to have MDL for the device. Health Canada then reviews Canadian MDL application and Premarket Review Document.The approved application and certificates are posted on the official website of Health Canada and then the device is marketed. The steps for market approval of a medical device in Canada are shown in Figure 3:

 

Figure 3: Steps for medical devices market approval in Canada

 

Turacoz Healthcare Solution (THS) always aims to keep professionals updated about rules and regulations of drugs and devices of different countries. Turacoz is dedicated in providing scientific/medical writing support to the industry and academia. With expertise in several clinical trial related documents like Investigator Brochures (IBs), Protocols, Clinical Study Reports (CSRs), Clinical Evaluation Report (CER) and Common Technical Documents (CTDs) Prescribing Information (PI), we aim to deliver the best quality and guideline compliant documents to the pharma and different sectors of healthcare industry.